153 related articles for article (PubMed ID: 15248757)
1. Crystallographic analysis reveals that anticancer clinical candidate L-778,123 inhibits protein farnesyltransferase and geranylgeranyltransferase-I by different binding modes.
Reid TS; Long SB; Beese LS
Biochemistry; 2004 Jul; 43(28):9000-8. PubMed ID: 15248757
[TBL] [Abstract][Full Text] [Related]
2. Theoretical studies on binding and specificity mechanisms of farnesyltransferase (FTase) and geranylgeranyltransferase type-I (GGTase-I) inhibitors by molecular modeling.
Zhou S
Comb Chem High Throughput Screen; 2014; 17(6):509-19. PubMed ID: 24444014
[TBL] [Abstract][Full Text] [Related]
3. Crystal structures of the anticancer clinical candidates R115777 (Tipifarnib) and BMS-214662 complexed with protein farnesyltransferase suggest a mechanism of FTI selectivity.
Reid TS; Beese LS
Biochemistry; 2004 Jun; 43(22):6877-84. PubMed ID: 15170324
[TBL] [Abstract][Full Text] [Related]
4. Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity.
Reid TS; Terry KL; Casey PJ; Beese LS
J Mol Biol; 2004 Oct; 343(2):417-33. PubMed ID: 15451670
[TBL] [Abstract][Full Text] [Related]
5. Farnesyltransferase and geranylgeranyltransferase I: structures, mechanism, inhibitors and molecular modeling.
Shen M; Pan P; Li Y; Li D; Yu H; Hou T
Drug Discov Today; 2015 Feb; 20(2):267-76. PubMed ID: 25450772
[TBL] [Abstract][Full Text] [Related]
6. Conversion of protein farnesyltransferase to a geranylgeranyltransferase.
Terry KL; Casey PJ; Beese LS
Biochemistry; 2006 Aug; 45(32):9746-55. PubMed ID: 16893176
[TBL] [Abstract][Full Text] [Related]
7. The crystal structure of human protein farnesyltransferase reveals the basis for inhibition by CaaX tetrapeptides and their mimetics.
Long SB; Hancock PJ; Kral AM; Hellinga HW; Beese LS
Proc Natl Acad Sci U S A; 2001 Nov; 98(23):12948-53. PubMed ID: 11687658
[TBL] [Abstract][Full Text] [Related]
8. Development of selective, potent RabGGTase inhibitors.
Stigter EA; Guo Z; Bon RS; Wu YW; Choidas A; Wolf A; Menninger S; Waldmann H; Blankenfeldt W; Goody RS
J Med Chem; 2012 Oct; 55(19):8330-40. PubMed ID: 22963166
[TBL] [Abstract][Full Text] [Related]
9. A novel protein geranylgeranyltransferase-I inhibitor with high potency, selectivity, and cellular activity.
Peterson YK; Kelly P; Weinbaum CA; Casey PJ
J Biol Chem; 2006 May; 281(18):12445-50. PubMed ID: 16517596
[TBL] [Abstract][Full Text] [Related]
10. Dual protein farnesyltransferase-geranylgeranyltransferase-I inhibitors as potential cancer chemotherapeutic agents.
deSolms SJ; Ciccarone TM; MacTough SC; Shaw AW; Buser CA; Ellis-Hutchings M; Fernandes C; Hamilton KA; Huber HE; Kohl NE; Lobell RB; Robinson RG; Tsou NN; Walsh ES; Graham SL; Beese LS; Taylor JS
J Med Chem; 2003 Jul; 46(14):2973-84. PubMed ID: 12825937
[TBL] [Abstract][Full Text] [Related]
11. Targeted reengineering of protein geranylgeranyltransferase type I selectivity functionally implicates active-site residues in protein-substrate recognition.
Gangopadhyay SA; Losito EL; Hougland JL
Biochemistry; 2014 Jan; 53(2):434-46. PubMed ID: 24344934
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and characterization of piperazinedione-based dual protein inhibitors for both farnesyltransferase and geranylgeranyltransferase-I.
Qiao Y; Gao J; Qiu Y; Wu L; Guo F; Lo KK; Li D
Eur J Med Chem; 2011 Jun; 46(6):2264-73. PubMed ID: 21440964
[TBL] [Abstract][Full Text] [Related]
13. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
14. Reaction path of protein farnesyltransferase at atomic resolution.
Long SB; Casey PJ; Beese LS
Nature; 2002 Oct; 419(6907):645-50. PubMed ID: 12374986
[TBL] [Abstract][Full Text] [Related]
15. Genetic evidence for in vivo cross-specificity of the CaaX-box protein prenyltransferases farnesyltransferase and geranylgeranyltransferase-I in Saccharomyces cerevisiae.
Trueblood CE; Ohya Y; Rine J
Mol Cell Biol; 1993 Jul; 13(7):4260-75. PubMed ID: 8321228
[TBL] [Abstract][Full Text] [Related]
16. A mutant form of human protein farnesyltransferase exhibits increased resistance to farnesyltransferase inhibitors.
Del Villar K; Urano J; Guo L; Tamanoi F
J Biol Chem; 1999 Sep; 274(38):27010-7. PubMed ID: 10480914
[TBL] [Abstract][Full Text] [Related]
17. Novel and selective imidazole-containing biphenyl inhibitors of protein farnesyltransferase.
Curtin ML; Florjancic AS; Cohen J; Gu WZ; Frost DJ; Muchmore SW; Sham HL
Bioorg Med Chem Lett; 2003 Apr; 13(7):1367-71. PubMed ID: 12657284
[TBL] [Abstract][Full Text] [Related]
18. The basis for K-Ras4B binding specificity to protein farnesyltransferase revealed by 2 A resolution ternary complex structures.
Long SB; Casey PJ; Beese LS
Structure; 2000 Feb; 8(2):209-22. PubMed ID: 10673434
[TBL] [Abstract][Full Text] [Related]
19. A novel class of highly potent, selective, and non-peptidic inhibitor of Ras farnesyltransferase (FTase).
Lee H; Lee J; Lee S; Shin Y; Jung W; Kim JH; Park K; Kim K; Cho HS; Ro S; Lee S; Jeong SW; Choi T; Chung HH; Koh JS
Bioorg Med Chem Lett; 2001 Dec; 11(23):3069-72. PubMed ID: 11714612
[TBL] [Abstract][Full Text] [Related]
20. Amino acid residues that define both the isoprenoid and CAAX preferences of the Saccharomyces cerevisiae protein farnesyltransferase. Creating the perfect farnesyltransferase.
Caplin BE; Ohya Y; Marshall MS
J Biol Chem; 1998 Apr; 273(16):9472-9. PubMed ID: 9545274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
